This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (54)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Not Just Lipid Levels

Steven E. Nissen, MD

JAMA. 2004;292:1365-1367.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

For more than a decade, statin drugs have accumulated a remarkable record of successful clinical trials, demonstrating robust evidence for reduction in clinical events, including myocardial infarction, stroke, and cardiovascular death in primary and secondary prevention populations.^1-4 Recent trials have shown that intensive statin therapy is superior to moderate therapy for reducing morbidity following an acute coronary syndrome (ACS) event^5-6 and for slowing the progression of coronary atherosclerosis.⁷ Statin trials have also demonstrated a favorable safety profile with only rare and isolated cases of serious toxicity.⁸ Given the spectacular success of this class of drugs, the failure of a statin clinical trial to meet its prespecified objective and evidence of an adverse safety profile are unusual and mandate careful analysis of potential responsible factors.

Phase Z of the A to Z trial,⁹ published in this issue of JAMA, is to date the largest trial testing . . . [Full Text of this Article]

Author Affiliation: Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

High-Dose Statins and Atherosclerosis Regression
Sid C. Port
JAMA. 2006;296(15):1836.
EXTRACT | FULL TEXT  

High-Dose Statins and Atherosclerosis Regression
Yoseph Rozenman
JAMA. 2006;296(15):1836.
EXTRACT | FULL TEXT  

High-Dose Statins and Atherosclerosis Regression
Clemens von Birgelen and Marc Hartmann
JAMA. 2006;296(15):1837.
EXTRACT | FULL TEXT  

High-Dose Statins and Atherosclerosis Regression—Reply
Steven E. Nissen
JAMA. 2006;296(15):1837.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial
James A. de Lemos, Michael A. Blazing, Stephen D. Wiviott, Eldrin F. Lewis, Keith A. A. Fox, Harvey D. White, Jean-Lucien Rouleau, Terje R. Pedersen, Laura H. Gardner, Robin Mukherjee, Karen E. Ramsey, Joanne Palmisano, David W. Bilheimer, Marc A. Pfeffer, Robert M. Califf, Eugene Braunwald, and for the A to Z Investigators
JAMA. 2004;292(11):1307-1316.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Does Simvastatin Cause More Myotoxicity Compared with Other Statins?
Backes et al.
The Annals of Pharmacotherapy 2009;43:2012-2020.
ABSTRACT | FULL TEXT  

FDA Guidance on Off-Label Promotion and the State of the Literature From Sponsors
Psaty and Ray
JAMA 2008;299:1949-1951.
FULL TEXT  

Methods of detecting atherosclerosis in non-cardiac surgical patients; the role of biochemical markers
Howard-Alpe et al.
Br J Anaesth 2006;97:758-769.
ABSTRACT | FULL TEXT  

Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects
Bauersachs et al.
Cardiovasc Res 2006;72:438-446.
ABSTRACT | FULL TEXT  

High-dose statins and atherosclerosis regression.
Port
JAMA 2006;296:1836-1836.
FULL TEXT  

Modulation of CD4+CD28null T Lymphocytes by Tumor Necrosis Factor-{alpha} Blockade in Patients With Unstable Angina
Rizzello et al.
Circulation 2006;113:2272-2277.
ABSTRACT | FULL TEXT  

The Verdict Is Still Out
Scirica et al.
Circulation 2006;113:2128-2151.
FULL TEXT  

A Tale of Two Trials: A Comparison of the Post-Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT-TIMI 22
Wiviott et al.
Circulation 2006;113:1406-1414.
ABSTRACT | FULL TEXT  

Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board
Ray and Stein
NEJM 2006;354:194-201.
FULL TEXT  

Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome
Szapary et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:182-188.
ABSTRACT | FULL TEXT  

Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis
Robinson et al.
J Am Coll Cardiol 2005;46:1855-1862.
ABSTRACT | FULL TEXT  

In-Hospital Initiation of Statin Therapy in Acute Coronary Syndromes: Maximizing the Early and Long-term Benefits
Fonarow
Chest 2005;128:3641-3651.
ABSTRACT | FULL TEXT  

White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin
Stewart et al.
Circulation 2005;111:1756-1762.
ABSTRACT | FULL TEXT  

Intensive Lipid-Lowering Therapy in Patients with Coronary Heart Disease
Lauderdale and Sheehan
The Annals of Pharmacotherapy 2005;39:329-334.
ABSTRACT | FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
Crouse
JAMA 2005;293:36-36.
FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
Mitchel
JAMA 2005;293:37-37.
FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
Davidson
JAMA 2005;293:38-38.
FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes--Reply
Nissen
JAMA 2005;293:39-39.
FULL TEXT  

High-Dose Statins in Acute Coronary Syndromes
Isley
JAMA 2005;293:37-38.
FULL TEXT  

Another Outcomes Test of Intensive Statin Therapy After ACS
Journal Watch Cardiology 2004;2004:1-1.
FULL TEXT